Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
Abbreviations
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
JakaviⓇ - JAK 1/2 inhibitor
Study
Indication
Phase
Patients
NCT04097821 ADORE (CINC424H12201)
Myelofibrosis
Phase 1/2
130
Primary Outcome
Measures
Arms Intervention
Incidence of dose limiting toxicities within the first 2 cycles
Response rate at the end of cycle 6
Ruxolitinib
Ruxolitinib+Siremadlin
Ruxolitinib+Crizanlizumab
Ruxolitinib+MBG453
Ruxolitinib+LTT462
Ruxolitinib+NIS793
Patients with Myelofibrosis (MF)
Target Patients
Read-out Milestone(s)
Publication
2024
TBD
105 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation